External broker reports(aggregated public sources), CMB International

CMB International

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>In 1Q23, RemeGen recorded revenue of RMB168mn, mostly from the product sales of RC18 and RC48, compared to RMB202mn in 4Q22 (-17% QoQ) and RMB150mn in 1Q22 (+12% YoY).</li><li>The Company maintained the FY23 revenue target of no less than RMB1,250mn unchanged.</li><li>According to the management, the Company intentionally slowed down the shipment volume of RC18 in 1Q23, considering high product sales in 1Q could have a negative impact on the NDRL renewal of RC18 late this year. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

In 1Q23, RemeGen recorded revenue of RMB168mn, mostly from the product sales of RC18 and RC48, compared to RMB202mn in 4Q22 (-17% QoQ) and RMB150mn in 1Q22 (+12% YoY).The Company maintained the FY23 revenue target of no less than RMB1,250mn unchanged.According to the management, the Company intentionally slowed down the shipment volume of RC18 in 1Q23, considering high product sales in 1Q could have a negative impact on the NDRL renewal of RC18 late this year. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

RemeGen (9995 HK) – Expect sales recovery from 2Q

Remegen

RemeGen (9995 HK) – Expect sales recovery from 2Q